No Data
CanSino Biologics Enrolls First Patient in Phase 1 Trial for Haemophilus Influenzae Vaccine
Cansino Biologics Inc. (688185): Meningococcal vaccine sales going smoothly, turning losses into profits in the third quarter.
Investment Highlights: The loss narrowed in the first three quarters, turning from a loss to a profit in the third quarter. In the first three quarters of 2024, the company achieved revenue of 0.567 billion yuan, a year-on-year increase of 222.88%; net income attributable to mother -0.222 billion yuan, narrowing year-on-year.
Cansino Biologics Inc.: The freeze-dried b-type influenza haemophilus influenzae combination vaccine has initiated Phase I clinical trials and completed the enrollment of the first subject.
Gelonghui, November 15 | Cansino Biologics Inc. announced that the clinical trial phase I for its freeze-dried b-type Haemophilus influenzae conjugate vaccine (Hib vaccine) has officially commenced recently, and the first subject has been enrolled. The Hib vaccine is part of the combined vaccine based on the DTP components that the company is developing. The phase I clinical trial is a randomized, partially blinded, positive-controlled clinical trial aimed at evaluating the safety and immunogenicity of this vaccine in individuals aged 2 months and older. The company cautions that vaccine development is challenging and lengthy, with uncertainties regarding the progress and results of clinical trials and the commercialization of the products.
Cansinobio (06185.HK) has completed the enrollment of the first subject for the acute lower respiratory tract infection vaccine.
Cansinobio (06185.HK) announced that its 'freeze-dried b-type influenza haemophilus influenzae B conjugate vaccine' (Hib vaccine) has recently officially initiated phase I clinical trials and completed the enrollment of the first subject. According to the introduction, haemophilus influenzae is a gram-negative bacillus and one of the main pathogens of acute lower respiratory tract infections in children. As for the above-mentioned vaccine, it is expected to induce humoral immunity against Hib after administration, providing protection to the vaccinee. Cansinobio stated that it is developing a combination vaccine based on acellular pertussis, with the in-development Hib vaccine being one of its components, as a monovalent vaccine not yet approved for market launch.
Cansino Biologics Inc. (688185.SH): The freeze-dried type B influenza Haemophilus influenzae conjugate vaccine has started Phase I clinical trials and has completed the enrollment of the first subject.
On November 15, GeLongHui announced that cansino biologics inc. (688185.SH) officially initiated Phase I clinical trials for the freeze-dried b-type influenza haemophilus influenzae type b vaccine (referred to as "Hib vaccine") recently and completed the first subject's enrollment. The company's developed Hib vaccine is composed of purified Hib capsular polysaccharides covalently bound with diphtheria toxoid protein, in freeze-dried form, expected to induce humoral immunity against Hib post-vaccination, providing protective effects for vaccinees.
Results: CanSino Biologics Inc. Confounded Analyst Expectations With A Surprise Profit
No Data
No Data